On August 21, 2019 PER Global, a worldwide leading resource for continuing medical education (CME), reported that it will host the live CME-accredited Medical Crossfire: Leveraging the Lung Cancer Team in Stage III NSCLC With Immuno-Oncology Strategies, adjunct to the IASLC 2019 World Conference on Lung Cancer (Press release, Physicians’ Education Resource, AUG 21, 2019, View Source [SID1234538912]). The program will take place on Sunday, 08 Sept. 2019 from 11:30 a.m. to 13:30 p.m. in Hall 6 at Fira de Barcelona – Gran Via venue in Spain.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Medical Crossfire will be chaired by Naiyer A. Rizvi, M.D., professor of medicine; director, thoracic oncology; co-director, cancer immunotherapy program; and the Price Family Professor of Medicine, Columbia University Irving Medical Center.
"The contemporary treatment of NSCLC requires the coordination and cooperation of the full treatment team," said Phil Talamo, president of PER Global. "Through our Medical Crossfire format, we will bring together pathology, medical oncology, and radiation oncology to foster a detailed discussion of the current and future of care for patients with non-small cell lung cancer (NSCLC)."
The variety of treatment options for patients with NSCLC continue to evolve, further complexifying the treatment landscape for this multifaceted illness. This program will feature a multidisciplinary faculty, world-renowned experts in medical oncology, radiation oncology and surgery. Current standards of care in patients with unresectable stage 3 NSCLC will be addressed, including the current and future roles of biomarkers and management of immune-related adverse events. Throughout the program, expert Medical Crossfire discussion panels will illustrate how experts address challenges in the implementation of immunotherapy for patients with locally advanced NSCLC.
The faculty panel includes the following experts:
Keith M. Kerr, FRCPath, consultant pathologist, department of pathology, Aberdeen Royal Infirmary, and professor of pulmonary pathology, Aberdeen University Medical School.
Suresh Senanm, MRCP, FRCR, Ph.D., professor of clinical experimental radiotherapy, department of radiation oncology. Amsterdam University Medical Center.
Rolf A. Stahel, M.D., professor in the oncology clinic, University Hospital Zurich.
This live activity is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) for 2 European CME credits for physicians. Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits. For more information and to register, click here.